DaVita Clinical Research Presents Research Results at the American Nephrology Nurses Association National Symposium



Estimated read time: 4-5 minutes

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

[STK] NYSE:DVA

[IN] HEA MTC PHA

[SU]

-- WITH PHOTO -- TO HEALTH, AND NATIONAL EDITORS:

DaVita Clinical Research Presents Research Results at the American

Nephrology Nurses Association National Symposium

ANAHEIM, Calif., April 14, 2014 /PRNewswire-USNewswire/ -- DaVita

Clinical Research (DCR) (NYSE: DVA), a specialty contract research

organization with services spanning the full spectrum of drug and

device development, today announced that company representatives will

present four abstracts at the American Nephrology Nurses Association

(ANNA) 45th National Symposium scheduled for April 13-16, 2014 in

Anaheim, Calif.

ANNA is designed to provide an educational and networking environment

for nephrology nurses and practice administrators to expand knowledge,

enhance clinical skills, and translate evidence into daily practice.

"At DaVita, we're committed to improving the care of patients with

renal disease by focusing on translational research," said Mahesh

Krishnan, M.D., M.P.H., M.B.A., F.A.S.N., vice president clinical

innovation and public policy at DaVita. "Presenting our research

initiatives here at ANNA creates an ideal platform to translate those

findings into clinical care for kidney patients."

Researchers from DaVita, the dialysis division of DaVita Healthcare

Partners Inc., and DCR will present results from a number of

innovative clinical improvement programs originating from DaVita and

its research partners. DCR seeks to advance the future of medicine,

the practice of medicine and to innovate through personalized

medicine. DCR and DaVita share a dedication to improving the health

and quality of life for kidney care patients.

DaVita will focus on meaningful research initiatives in end-stage

renal disease, including:

-- "Choice of Drain Systems and Associated Peritonitis Rates in

Automated Peritoneal Dialysis Patients," oral presentation by Michelle

Cassin, R.N., C.P.D.N. on Monday, April 14 in Abstract Concurrent

Session #162, from 5:35 p.m.-5:55 p.m.

-- "Hemodialysis Session Length Has a Dose Relationship With Hazard

Rates of Cause-Specific Hospitalization and Mortality," oral

presentation by Irina Goykhman, R.N., B.S.N., M.B.A. on Monday, April

14 in Abstract Concurrent Session #161, from 4:20 p.m.- 4:40 p.m.

-- "A Pilot Quality Improvement Program to Minimize Catheter-Related

Bloodstream Infection in an Outpatient Hemodialysis Setting," poster

presentation by Nancy Culkin, B.S.N., R.N., C.N.N.

-- "A Standardized Algorithm for Peritonitis Surveillance," poster

presentation by Michelle Cassin, R.N., C.P.D.N.

Poster presentations will be held Monday, April 14, 2:45 p.m.-4:15

p.m. and Tuesday, April 15, 9:00 a.m.-10:15 a.m.

DaVita, DaVita Clinical Research, and DCR are trademarks or registered

trademarks of DaVita Healthcare Partners Inc.

About DaVita DaVita is the dialysis division of DaVita HealthCare

Partners Inc., a Fortune 500@ company that, through its operating

divisions, provides a variety of health care services to patient

populations throughout the United States and abroad. A leading

provider of kidney care in the United States, DaVita delivers dialysis

services to patients with chronic kidney failure and end stage renal

disease. DaVita strives to improve patients' quality of life by

innovating clinical care, and by offering integrated treatment plans,

personalized care teams and convenient health-management services. As

of Dec. 31, 2013, DaVita operated or provided administrative services

at 2,074 outpatient dialysis centers located in the United States

serving approximately 163,000 patients. The company also operated 73

outpatient dialysis centers located in ten countries outside the

United States. DaVita supports numerous programs dedicated to creating

positive, sustainable change in communities around the world. The

company's leadership development initiatives and social responsibility

efforts have been recognized by Fortune, Modern Healthcare, Newsweek

and WorldBlu. For more information, please visit DaVita.com.

About DaVita Clinical Research DaVita Clinical Research (DCR), a

wholly owned subsidiary of DaVita HealthCare Partners Inc. (NYSE:

DVA), uses its extensive, applied database and real-world healthcare

experience to assist pharmaceutical and medical device companies in

the design, recruitment and completion of retrospective, prospective

pragmatic and clinical trials. DCR's scientific and clinical expertise

spans the lifecycle of product development with more than 150 client

companies. DCR's Biorepository, Early Clinical Research unit (Phase

I-IIa) and Clinical Development (Phase IIb through post-marketing)

network of physicians and investigative sites, data research, Health

Economics & Outcomes Research, and Medical Communications are focused

on providing world-class research in both complex/specialty

populations and therapeutic areas, and especially in CKD and ESRD

populations. To learn more about DCR, visit

www.davitaclinicalresearch.com.

Logo - http://photos.prnewswire.com/prnh/20140212/DC63568LOGO

Contact Information Media: Bianca Violante Office: (303) 876-661

Mobile: (443) 417-6044 Bianca.Violante@DaVita.com

SOURCE DaVita Clinical Research

-0- 04/14/2014

/Photo: http://photos.prnewswire.com/prnh/20140212/DC63568LOGO

(NYSE:DVA) /

CO: DaVita Clinical Research

ST: California

IN: HEA MTC PHA

PRN

-- DC04086 --

0000 04/14/2014 10:12:00 EDT http://www.prnewswire.com

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

The Associated Press

    SIGN UP FOR THE KSL.COM NEWSLETTER

    Catch up on the top news and features from KSL.com, sent weekly.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.

    KSL Weather Forecast